Gilead to BEAT Expectations and 4 Must-See Stock Analyses

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Gilead Sciences Inc. (NASDAQ:GILD): According to Deutsche Bank, Stribild’s annual price of $28,500 is sensible and Gilead’s launch of its recently approved HIV treatment will beat expectations. The firm estimates Stribild sales totaling $85 million during 2012 and $746 million during 2013, which is above current consensus of $45 million in 2012 and $400 million in 2013. Deutsche maintains a Buy rating and a $68 price target on the stock.

Don’t Miss: What Has Tiffany’s and Best Buy SMILING?

Knight Transportation Inc. (NYSE:KNX): According to Citigroup, its Truckload sector channel checks suggested that after July freight was in-line with expected seasonality, August volumes were slightly weaker than predicted. Citi recommends continuing to be selective in the space because of challenging near-term fundamentals, and the firm keeps Buy ratings on Knight Transportation and Werner (NYSE:WEN). The firm gives Neutral ratings to J.B. Hunt (NASDAQ:JBHT) and Swift Transportation (NYSE:SWFT).

Mattress Firm Holding Corp (NASDAQ:MFRM): Piper Jaffray claims that it remains favorable regarding Mattress Firm shares into the company’s Q2 results on September 6 as industry sales are still healthy and the company’s product margin improvement has continued to accelerate. Piper views the more than 40 percent short interest in the stock as surprisingly high, and believes it may drive further upside after the Q2 results. Piper maintains an Overweight rating on Mattress Firm with a $44 price target.

Perfect World Co., Ltd. (NASDAQ:PWRD): According to Citigroup, shares of Perfect World will experience near-term pressure due to the company’s weak revenue guidance and lack of catalysts prior to the launch of Condor Heroes in late September. Citi believes that shares of Perfect World are trading at distress levels, and it keeps a Buy rating on the stock with a $20.41 price target after the company’s Q2 results.

VMware, Inc. (NYSE:VMW): After VMware’s analyst meeting, Jefferies states that the company is still undergoing significant changes, which include rolling back price changes and new management suites. Jefferies thinks that the transition creates uncertainty on VMware’s near-term growth, and it maintains a Hold rating on the stock.

Don’t Miss: Here’s How Apple Plans to EXTERMINATE Samsung.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business